Watch hVIVO’s July 2024 Capital Markets Day here
At hVIVO, we play an important role in improving global health by supporting the clinical development of medicinal products. As a growing organisation, we recognise the importance of continually improving our governance and prioritising social and environmental values in all our work.
We are committed to operating as a responsible business; and as part of this commitment, we are working hard to continuously improve our environmental, social and governance protocols and policies. hVIVO has established a cross business working group, called the ESG Group, which focuses on identifying risks and opportunities related to climate change and other social and governance topics. The ESG Group is led by our CEO, Yamin ‘Mo’ Khan, and includes cross-company representatives, ensuring a well-rounded and integrated approach to ESG matters, with support from CBRE’s sustainability team. The ESG Group reports directly to the Audit and Risk Committee which is responsible for overseeing the Company’s ESG reporting and providing recommendations to the Board for final review and endorsement.
At hVIVO, we are aware of our pivotal role in facilitating our clients' endeavours to expedite the development of vital medicines through our comprehensive drug development consulting and clinical trial services. This commitment to social responsibility aligns with our vision of transforming global healthcare by revolutionising the drug development process through scientific ingenuity.
Our team is the key to our success. At hVIVO, we foster a collaborative, inclusive, and supportive workplace where employee well-being, equality, and professional growth are our priorities. Through flexible working, training, and ESG-driven initiatives, we empower our people to thrive and succeed together.
We prioritise the safety and well-being of our trial participants and are committed to upholding the highest ethical standards in clinical research, including data privacy and protection. We value the feedback from our participants and continually seek to improve our processes to ensure their voices are heard.
Social and community investment involves strategically allocating resources to initiatives that promote positive social impact and foster community development. By supporting projects focused on education, healthcare, and sustainable development, we can contribute to the well-being and resilience of communities, creating a lasting positive influence.
hVIVO is dedicated to environmental sustainability, achieving ISO 14001 certification at our Canary Wharf site in 2024 and embedding sustainable practices across our operations. From reducing waste and emissions to improving energy efficiency and sourcing responsibly, we continually enhance our environmental performance in line with our ESG goals.
We are committed to ethical and compliant business practices, upholding the highest standards of governance, transparency, and regulatory compliance across all operations. Through robust quality systems, training, and oversight, we aim to protect human rights, ensure participant safety, and maintain our strong record of integrity.
Yamin 'Mo' Khan
CEO & Head of the ESG Group
“At hVIVO, we have a clear vision: to transform global healthcare by revolutionising the drug development process through scientific ingenuity. This vision has sustainability, ethical governance, and social responsibility embedded into every aspect of our operations. As we continue to Optimise, Scale, and Diversify the business, our commitment to ESG principles plays a key role in our decision-making.
In 2024, we made significant strides in delivering on our vision. The launch of our state-of-the-art facility in Canary Wharf has strengthened our ability to conduct more studies with increased efficiency, and with expanded service offerings, supporting a growing number of biopharma clients in their mission to address unmet medical needs. We broadened our range of human challenge models in 2024, and with the addition of CL-3 capabilities, we can provide our world leading HCTs to support drug development in more disease indications than ever before. I am proud that we successfully achieved an Ecovadis sustainability rating in 2024.
An important milestone in 2024 was achieving ISO 14001 accreditation for our new Canary Wharf site, with plans to expand this across our other sites in the years ahead. Energy-efficient air handling systems, waste reduction initiatives, and responsible food sourcing are just some of the steps we have taken to ensure environmentally responsible operations. As we grow, we will continue to invest in renewable energy solutions and sustainable infrastructure.
Our team is the driving force behind our success. We remain focused on cultivating an inclusive and open working environment across the Group, supported by our policies, initiatives, and events. With the acquisition of CRS Mannheim, CRS Kiel, and Cryostore in 2025, we look forward to bringing our collaborative culture and ESG focus to these new subsidiaries.
Through our Volunteer Leave Policy and charitable donation initiatives, we empower employees to give back to the communities in which we operate. In 2024, we expanded our partnerships with local charities and have exciting plans for the year ahead to expand these initiatives further to give back to the community and support the next generation of scientists.
hVIVO is at the forefront of scientific innovation, but our success is defined by more than just financial success. It is measured by our ability to operate responsibly, ethically, and sustainably while driving meaningful change in global healthcare. I would like to sincerely thank our employees, trial participants, and partners for their dedication to scientific research. Together, we can deliver on our vision to transform global healthcare by revolutionising the drug development through scientific ingenuity.”
Sign up to our emails and follow us on social media to keep up to date with hVIVO.
